Neion Bio, a company focused on reinventing biopharmaceutical manufacturing through genetic engineering and stem cell biology, has closed a $23.0M Series A funding round. Its platform aims to overhaul the production process for complex molecules, promising orders of magnitude superior cost, scalability, and resiliency compared to current methods.
The fresh capital will accelerate Neion Bio's mission to democratize medicine by making advanced biomanufacturing more accessible and efficient, moving beyond traditional constraints in drug production.


.png&w=3840&q=75)












